Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. It provides liquid and lyophilized vials, pre-filled syringes, 3-pc ophthalmic droppers, pre-mix bags, dry and liquid syrups-bottles, tables, soft gels, capsules, suppositories, liquid and emulsion injectables in ampoules and vials, topicals, and sachets. The company was incorporated in 1990 and is headquartered in Chennai, India.
Stock data | 2023 | Change |
---|---|---|
Price | $23.44 | N/A |
Market Cap | $1.78B | N/A |
Shares Outstanding | 75.83M | 0.17% |
Employees | 1.64K | N/A |
Shareholder Equity | 19.07B | 26.32% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.48 | N/A |
P/S Ratio | 10.18 | N/A |
P/B Ratio | 0.09 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0024 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $174.65M | N/A |
Earnings | $44.89M | N/A |
EPS | 49.18 | N/A |
Earnings Yield | 2.10 | N/A |
Gross Margin | 0.5478 | N/A |
Operating Margin | 0.27 | N/A |
Net income margin | 0.257 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $260.94M | N/A |
Total Debt | $619.19K | N/A |
Cash on Hand | $86.28M | N/A |
Debt to Equity | 0.0018 | -0.67% |
Cash to Debt | $139.34 | -52.68% |
Current Ratio | $5.80 | -7.18% |